Dermorphin Powerful Analgesia CAS:77614-16-5
Dermorphin, a naturally occurring opioid peptide, was first isolated from the skin secretions of South American frogs belonging to the Phyllomedusa genus. This heptapeptide (seven-amino-acid chain) has garnered significant scientific interest due to its extraordinary analgesic potency—reportedly 30–40 times stronger than morphine in vivo.
Introduction
Dermorphin, a naturally occurring opioid peptide, was first isolated from the skin secretions of South American frogs belonging to the Phyllomedusa genus. This heptapeptide (seven-amino-acid chain) has garnered significant scientific interest due to its extraordinary analgesic potency-reportedly 30–40 times stronger than morphine in vivo. Unlike traditional opioids, dermorphin's unique structural features, including a rare D-amino acid residue, grant it enhanced stability and receptor selectivity. While not approved for human use, it serves as a critical tool in pain research and veterinary medicine. This article delves into its features, applications, benefits, dosing protocols, pharmacokinetics, and post-translational modifications (PTCs), offering a novel synthesis of current knowledge.
Features of Dermorphin
1. Structural Uniqueness
Dermorphin's sequence (Tyr-D-Ala-Phe-Gly-Tyr-Pro-Ser-NH₂) includes a D-alanine residue at position 2-a rare post-translational modification (PTC) in eukaryotic organisms. This D-configuration confers resistance to proteolytic enzymes, prolonging its half-life and enhancing bioavailability. The peptide's amphipathic nature (containing both hydrophobic and hydrophilic regions) facilitates interactions with lipid membranes and opioid receptors.
2. Mechanism of Action
Dermorphin primarily agonizes μ-opioid receptors (MORs), which are central to pain modulation. Unlike morphine, it exhibits biased agonism, preferentially activating G-protein signaling pathways over β-arrestin recruitment. This bias may reduce side effects like respiratory depression and tolerance, which are linked to β-arrestin activation.
3. Pharmacokinetics
●Absorption: Poor oral bioavailability due to enzymatic degradation; effective via intravenous (IV), intrathecal, or subcutaneous routes.
●Distribution: Limited blood-brain barrier (BBB) penetration unless administered centrally.
●Metabolism: Degraded by peptidases in plasma and tissues, but the D-alanine residue slows this process.
●Excretion: Primarily renal, with metabolites detectable in urine.
4. Half-Life
In rodent studies, dermorphin's half-life ranges from 30–90 minutes, depending on the administration route. Its stability surpasses endogenous opioids like enkephalins but remains shorter than synthetic opioids like fentanyl.
Applications
1. Research Applications
●Pain Pathways: Used to study MOR signaling and biased agonism mechanisms.
●Neuropathic Pain Models: Effective in rodent models of chronic pain, offering insights into alternative analgesia.
●Receptor Dynamics: Helps elucidate MOR dimerization and cross-talk with other receptors (e.g., NMDA).
2. Veterinary Medicine
●Exotic Animal Analgesia: Deployed in amphibians and reptiles where traditional opioids fail due to metabolic differences.
●Equine Misuse: Illicitly used in horse racing to mask injuries, prompting strict doping controls.
3. Drug Development
●Template for Analogs: Synthetic derivatives (e.g., [D-Arg²]-dermorphin) aim to improve BBB penetration and reduce side effects.
●Biased Agonist Research: Informs the design of next-generation opioids with safer profiles.
Benefits Over Traditional Opioids
●Potency: Microgram doses achieve analgesia comparable to milligram doses of morphine.
●Reduced Side Effects: Biased signaling may lower risks of respiratory depression and gastrointestinal stasis.
●Stability: D-amino acid extends duration of action, minimizing frequent redosing.
●Species-Specific Efficacy: Effective in non-mammalian species, broadening veterinary applications.
Dosage and Administration
Experimental Protocols
●Rodent Studies: 10–50 µg/kg IV or intrathecal, yielding analgesia within 5–15 minutes.
●Avian/Reptilian Models: 5–20 µg/kg IM, adjusted for metabolic rate and body mass.
Human Considerations
No established guidelines due to lack of clinical trials. Anecdotal reports suggest doses as low as 1–5 µg/kg in unregulated contexts, posing significant overdose risks.
Cycle and Frequency
In chronic pain studies, rodents tolerate twice-daily dosing (20 µg/kg) for 7–10 days without marked tolerance. However, prolonged use upregulates glutamate receptors, potentially exacerbating hyperalgesia. Cycling protocols (e.g., 5 days on, 2 days off) mitigate receptor desensitization.
Post-Translational Modifications (PTCs)
The D-alanine residue in dermorphin results from a unique enzymatic epimerization during biosynthesis in frog skin glands. This PTC:
●Enhances Stability: Resists aminopeptidases, common in mammalian plasma.
●Influences Conformation: Alters peptide folding, optimizing receptor binding.
●Evolutionary Insight: Suggests convergent evolution between amphibian and opioid systems.
Challenges and Risks
1.Addiction Potential: High MOR affinity raises abuse liability, though less than heroin.
2.Legal Status: Classified as a Schedule I substance in many countries, restricting research.
3.Ethical Concerns: Illicit use in animals underscores need for stricter regulation.
Future Directions
●Targeted Delivery: Liposomal encapsulation or nanoparticle carriers to enhance BBB penetration.
●Hybrid Peptides: Fusion with enkephalin sequences to broaden receptor targeting.
●Clinical Translation: Advocacy for controlled trials in intractable pain cases.
Clinical Data
|
Trade names |
Tyrosyl-alanyl-phenylalanyl-glycyl-tyrosyl-prolyl-serinamide |
|
CAS |
77614-16-5 |
|
Molar mass |
802.886 |
|
Formula |
C40H50N8O10 |
|
Purity |
Above 98% |
|
Apprarance |
5mg/vial,10vials/box |
Any needs, please contact us
Email: Jasonraws106@gmail.com
WhatsApp: +86-15572565525
Telegram: +86-19128233885
Conclusion
Dermorphin exemplifies nature's ingenuity, offering a template for potent, selective analgesia. While its applications remain niche, ongoing research into its biased agonism and PTC-driven stability holds promise for safer pain therapies. Balancing innovation with ethical stewardship will be key to unlocking its full potential.
Hot Tags: dermorphin powerful analgesia cas:77614-16-5, China dermorphin powerful analgesia cas:77614-16-5 manufacturers, suppliers, factory
